Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
17 , sfae018 (2024)
Specifically, retatrutide is intended to activate the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor a combination that distinguishes it from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 receptor agonist)
Fasting glucose levels may begin declining within 3 to 5 days, with more substantial reductions becoming apparent after 1 to 2 weeks of consistent dosing
After menopause, I struggled with weight loss
US$ 21.35
US$ 28.89
US$ 23.50
US$ 25.22
US$ 27.52
US$ 28.10
